Abstract The ESR1 ligand–binding mutations were unveiled a number of years ago and are the most common genetic mechanism acquired resistance to endocrine treatment, particularly, aromatase inhibitors. discovery these was enabled after advancements in sequencing technologies when metastatic tissue samples interrogated. domain activating that lead constitutive ligand-independent activity, which e...